多组学技术在代谢相关脂肪性肝病临床异质性研究中的应用

doi:10.16138/j.1673-6087.2026.02.03

内科理论与实践 ›› 2026, Vol. 21 ›› Issue (02): 119-123.doi: 10.16138/j.1673-6087.2026.02.03

多组学技术在代谢相关脂肪性肝病临床异质性研究中的应用

丁晶晶, 柴进()

陆军军医大学第一附属医院消化内科代谢相关脂肪性肝病医学研究中心胆汁淤积肝病中心，重庆　400038

收稿日期:2026-02-20 修回日期:2026-04-04 接受日期:2026-04-14 出版日期:2026-04-25 发布日期:2026-06-15
通讯作者: 柴进 E-mail：jin.chai@cldcsw.org
作者简介:作者贡献/Authors’ Contributions丁晶晶负责文献搜集及文章初稿起草；柴进负责文章撰写指导与最终审阅。
基金资助:
国家科技重大专项（新突发与重大传染病防控）(2025ZD101906400);国家自然科学基金杰出青年科学基金项目(82325008);国家自然科学基金青年科学基金项目(82500717)

Multi-omics technologies in the study of clinical heterogeneity of metabolic associated fatty liver disease

DING Jingjing, CHAI Jin()

Department of Gastroenterology, Metabolic Dysfunction-Associated Steatotic Liver Disease Medical Research Center, Cholestatic Liver Disease Center, the First Hospital Affiliated to Army Medical University, Chongqing 400038,China

Received:2026-02-20 Revised:2026-04-04 Accepted:2026-04-14 Online:2026-04-25 Published:2026-06-15

摘要/Abstract

摘要：

代谢相关脂肪性肝病（metabolic associated fatty liver disease，MAFLD）是全球患病率最高的慢性肝病，已成为重要的公共卫生问题。MAFLD不仅损害肝功能，还与多系统疾病发病风险升高密切相关，包括心血管疾病、慢性肾脏病和 2型糖尿病。然而，当前MAFLD治疗仍面临有效药物匮乏、药物疗效存在显著局限等问题。其核心挑战在于MAFLD患者群体存在高度异质性。本文系统综述了多组学技术（包括全基因组关联分析、转录组测序、蛋白质组学和代谢组学）在解析MAFLD异质性方面取得的突破性研究成果，总结了基于上述多组学特征界定的MAFLD亚型及其分子机制，从而为MAFLD患者的精准风险分层及个体化治疗靶点的开发提供重要科学依据。

Abstract:

Metabolic associated fatty liver disease (MAFLD) is the most prevalent chronic liver disease worldwide and has become an important public health issue. MAFLD not only impairs liver function but is also closely associated with an increased risk of multi-system diseases, including cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus. However, current treatment for MAFLD still faces challenges such as a lack of effective drugs and significant limitations in drug efficacy. The core challenge lies in the high degree of clinical heterogeneity among MAFLD patients. This article systematically reviews the breakthrough research findings achieved by multi-omics technologies (including genome-wide association analysis, transcriptome sequencing, proteomics, and metabolomics) in deciphering the heterogeneity of MAFLD, and summarizes the MAFLD subtypes and their molecular mechanisms defined based on the above multi-omics characteristics, thereby providing a critical scientific basis for precision risk stratification and the development of personalized therapeutic targets for MAFLD patients.

Key words: metabolic associated fatty liver disease, clinical heterogeneity, multi-omics, proteomics, subtype

丁晶晶, 柴进. 多组学技术在代谢相关脂肪性肝病临床异质性研究中的应用[J]. 内科理论与实践, 2026, 21(02): 119-123.

DING Jingjing, CHAI Jin. Multi-omics technologies in the study of clinical heterogeneity of metabolic associated fatty liver disease[J]. Journal of Internal Medicine Concepts & Practice, 2026, 21(02): 119-123.

参考文献 24

[1]	Li QZ, Tan JX, Qin QZ, et al. Association between arterial stiffness and MASLD in US young adults: based on NHANES 2005-2018[J]. Am J Prev Cardiol,2025,22:101003. doi: 10.1016/j.ajpc.2025.101003
[2]	Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease[J]. J Hepatol,2018,68(2):230-237. doi: 10.1016/j.jhep.2017.10.031
[3]	Kim KS, Hong S, Han K, et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study[J]. BMJ,2024,384:e076388. doi: 10.1136/bmj-2023-076388
[4]	Moncho F, Benlloch S, Górriz JL. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management[J]. Clin Kidney J,2025,18(9):sfaf260. doi: 10.1093/ckj/sfaf260
[5]	Yoneda M, Yamamoto T, Honda Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan[J]. J Gastroenterol,2021,56(11):1022-1032. doi: 10.1007/s00535-021-01828-6
[6]	Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med,2024,390(6):497-509. doi: 10.1056/NEJMoa2309000
[7]	Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis:baseline characteristics and design of the phase 3 ESSENCE trial [J]. Aliment Pharmacol Ther, 2024, 60(11-12):1525-1533.
[8]	Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps[J]. Hepatology,2019,70(4):1457-1469. doi: 10.1002/hep.30626
[9]	Xu M, Gong R, Xie J, et al. Clinical characteristics of lean and non-lean non-alcoholic fatty liver disease: a cross-sectional study[J]. Nutr Metab (Lond),2025,22(1):40. doi: 10.1186/s12986-025-00927-y
[10]	Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO study)[J]. Hepatology,2023,78(1):272-283. doi: 10.1097/HEP.0000000000000329
[11]	Seko Y, Yamaguchi K, Shima T, et al. Clinical utility of genetic variants in PNPLA3 and TM6SF2 to predict liver-related events in metabolic dysfunction-associated steatotic liver disease[J]. Liver Int,2025,45(4):e16124. doi: 10.1111/liv.16124
[12]	Krawczyk M, Rau M, Schattenberg JM, et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study[J]. J Lipid Res,2017,58(1):247-255. doi: 10.1194/jlr.P067454
[13]	Shi X, Wei X, Koo I, et al. Metabolomic analysis of the effects of chronic arsenic exposure in a mouse model of diet-induced fatty liver disease[J]. J Proteome Res,2014,13(2):547-554. doi: 10.1021/pr400719u
[14]	Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism,2016,65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012
[15]	Jamialahmadi O, De Vincentis A, Tavaglione F, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease[J]. Nat Med,2024,30(12):3614-3623. doi: 10.1038/s41591-024-03284-0
[16]	Govaere O, Cockell S, Tiniakos D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis[J]. Sci Transl Med,2020,12(572):eaba4448. doi: 10.1126/scitranslmed.aba4448
[17]	Wang B, Yu H, Gao J, et al. Machine learning deciphers the significance of mitochondrial regulators on the diagnosis and subtype classification in non-alcoholic fatty liver disease[J]. Heliyon,2024,10(9):e29860. doi: 10.1016/j.heliyon.2024.e29860
[18]	He J, Xiao C, Li C, et al. Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression[J]. Liver Res,2023,7(2):145-155. doi: 10.1016/j.livres.2023.06.001
[19]	Ding J, Liu H, Zhang X, et al. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population[J]. Sci Transl Med,2024,16(772):eadh9940. doi: 10.1126/scitranslmed.adh9940
[20]	Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer[J]. Physiol Rev,2012,92(4):1515-1542. doi: 10.1152/physrev.00047.2011
[21]	Gautam J, Aggarwal H, Kumari D, et al. A methionine-choline-deficient diet induces nonalcoholic steatohepatitis and alters the lipidome, metabolome, and gut microbiome profile in the C57BL/6J mouse[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2024,1869(8):159545. doi: 10.1016/j.bbalip.2024.159545
[22]	Drummer CIV, Saaoud F, Sun Y, et al. Hyperlipidemia may synergize with hypomethylation in establishing trained immunity and promoting inflammation in NASH and NAFLD[J]. J Immunol Res,2021,2021:3928323. doi: 10.1155/2021/3928323
[23]	Alonso C, Fernández-Ramos D, Varela-Rey M, et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis[J]. Gastroenterology,2017,152(6):1449-1461. doi: 10.1053/j.gastro.2017.01.015
[24]	Martínez-Arranz I, Bruzzone C, Noureddin M, et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles[J]. Hepatology,2022,76(4):1121-1134. doi: 10.1002/hep.32427

多组学技术在代谢相关脂肪性肝病临床异质性研究中的应用

Multi-omics technologies in the study of clinical heterogeneity of metabolic associated fatty liver disease

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张璐, 王剑, 林勇. 代谢相关非肝硬化性门静脉高压：从初步认识到精准管理[J]. 内科理论与实践, 2026, 21(02): 171-175.
[2]	陈霞, 张如鸿. 基于蛋白质组学的肋软骨钙化和吸收问题分析在耳再造手术中的应用研究进展[J]. 组织工程与重建外科杂志, 2025, 21(4): 40-.
[3]	刘淦, 戴媛媛, 常文娇, 马筱玲. 脓毒症筛查技术进展[J]. 诊断学理论与实践, 2025, 24(06): 567-575.
[4]	王敬源, 范嘉裕, 张平平, 马洪运, 陈颖, 李刚, 金震东, 金钢, 王凯旋. 囊液性状可预测胰腺导管内乳头状黏液性肿瘤的良、恶性[J]. 外科理论与实践, 2025, 30(06): 509-516.
[5]	虞文嫣, 郭瑛, 唐源, 欧阳皖雁, 黄燕, 胡苏, 陶怡, 糜坚青. 多技术多组学融合视角下的多发性骨髓瘤伴髓外病变教学初探[J]. 诊断学理论与实践, 2025, 24(05): 562-565.
[6]	陈洪卫, 朱婷, 刘燕, 侯彦强, 范广建. 外周血Scimp可作为代谢相关脂肪性肝病肝硬化的生物诊断标志物——基于动物实验的研究[J]. 诊断学理论与实践, 2025, 24(01): 35-42.
[7]	郑鸿鲲, 单圣周, 季向阳, 等. 病理性瘢痕的多组学方法研究进展 [J]. 组织工程与重建外科杂志, 2024, 20(3): 362-.
[8]	周悦, 叶媚娜, 代秋颖, 等. 肉芽肿性乳腺炎病灶组织差异表达蛋白质筛选及关键分子验证[J]. 组织工程与重建外科杂志, 2024, 20(1): 75-.
[9]	周丽华, 沈茹, 屈柯暄, 王爱华, 陈有会, 袁志敏. ABO血型基因第7外显子695 T>C突变导致B_w11亚型的研究[J]. 诊断学理论与实践, 2024, 23(04): 392-397.
[10]	廖振宇, 赵起悟, 匡洁, 刘卓然, 孙寒星, 王越, 邱伟华, 陈曦, 严佶祺. 高细胞亚型甲状腺乳头状癌的侵袭性组织病理学特征研究[J]. 外科理论与实践, 2023, 28(06): 524-528.
[11]	陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰. 心血管转化研究的若干进展[J]. 内科理论与实践, 2022, 17(05): 369-372.
[12]	刘峰，殷善开. 衰老的生物学机制是什么?[J]. 上海交通大学学报, 2021, 55(Sup.1): 18-19.
[13]	周璐, 雷航, 洪叶, 金爽, 董永勤, 王学锋, 蔡晓红. 一个新的ABOA*等位基因导致的A_wB亚型及其分子机制研究[J]. 诊断学理论与实践, 2021, 20(06): 547-551.
[14]	王泽田, 吴春荣, 齐越, 徐丹, 孙科远, 唐建国. 外泌体蛋白质组学分析白念珠菌感染小鼠的标志物[J]. 外科理论与实践, 2021, 26(03): 262-268.
[15]	陈萍, 张水木, 雷航, 王钰箐, 陈宇, 王学锋, 蔡晓红. 血清学鉴定与基因检测互补验证ABO疑难血型的应用探讨[J]. 诊断学理论与实践, 2020, 19(1): 69-73.